Is Abciximab compatible with breastfeeding? Do we have alternatives for Abciximab?


March 23, 2018 (Low Risk)

Monoclonal antibody fragment that binds to platelet receptors inhibiting platelet aggregation. Used to treat angioplasty and unstable angina.

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic data: very high molecular weight, high percentage of platelet binding (Harder 1999) and short half-life, make it very unlikely it will pass into breast milk in significant amounts.

Due to its protein nature, it deteriorates in the gastrointestinal tract, not being absorbed. This low oral bioavailability would make it difficult for it to pass to the infant’s plasma ingesting breast milk, except in preterm infants and in the immediate neonatal period when there may be increased intestinal permeability.


Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.


  1. Abciximab Ficha técnica 2013 Full text (in our servers)
  2. Abciximab Data sheet 2013 Full text (in our servers)
  3. Harder S, Kirchmaier CM, Krzywanek HJ, Westrup D, Bae JW, Breddin HK. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects. Circulation. 1999Abstract